Journal ArticleDOI
Opening the lid on piano-stool complexes: An account of ruthenium(II)–arene complexes with medicinal applications
Reads0
Chats0
TLDR
The origins of the field are described, the design of compounds that inhibit enzymes are designed, the application of multinuclear systems to act as drug delivery vehicles, and the development of bioanalytical and biophysical methods are highlighted to help elucidate the mechanisms by which these compounds function.About:
This article is published in Journal of Organometallic Chemistry.The article was published on 2014-02-01. It has received 226 citations till now.read more
Citations
More filters
Journal ArticleDOI
Piano stool Ru(II)-arene complexes having three monodentate legs: A comprehensive review on their development as anticancer therapeutics over the past decade
TL;DR: In this paper , a review of the structural and molecular alterations in the design and development of Ru(II)-arene complexes with monodentate (cheifly P, N or S) ligand(s) for anticancer applications, and their behaviour in in vitro or in vivo, is presented.
Journal ArticleDOI
Ruthenium and Osmium Complexes of Phosphine-Porphyrin Derivatives as Potential Bimetallic Theranostics: Photophysical Studies
Pierre D. Harvey,Pierre D. Harvey,Semra Tasan,Claude P. Gros,Charles H. Devillers,Philippe Richard,Pierre Le Gendre,Ewen Bodio +7 more
TL;DR: In this paper, a series of (η6-p-cymene)ruthenium(II)- and osmium-II complexes of porphyrin-phosphane derivatives have been synthesized as potential bimetallic theranostic candidates.
Journal ArticleDOI
Synthesis, Characterization, and Antimicrobial Activity of RhIII and IrIII β-Diketonato Piano-Stool Compounds
TL;DR: A series of RhIII and IrIII half-sandwich compounds of the type [(η5-Cp*R)M(β-diketonato)Cl] were synthesized and characterized, including 17 X-ray crystallographic structures.
Journal ArticleDOI
Arene–Ruthenium(II) Complexes with Bioactive ortho-Hydroxydibenzoylmethane Ligands: Synthesis, Structure, and Cytotoxicity
Riccardo Pettinari,Agnese Petrini,Fabio Marchetti,Claudio Pettinari,Tina Riedel,Bruno Therrien,Paul J. Dyson +6 more
TL;DR: In this paper, the synthesis of neutral arene-ruthenium(II) complexes (arene = p-cymene, hexamethylbenzene, and benzene) derived from the reaction of the appropriate arene−RRTH dimers and ortho-hydroxydibenzoylmethane (HDBH), a potent inhibitor of cell proliferation, is described.
Journal ArticleDOI
Design and synthesis of a DNA intercalative half-sandwich organoruthenium(II)–chromone complex: cytotoxicity evaluation and topoisomerase Iα inhibition assay
TL;DR: In this article, the authors reported the molecular design and synthesis of [Ru(η6-p-cymene)-(chromone)Cl] complex (1) as a potential topoisomerase I inhibitor.
References
More filters
Journal ArticleDOI
Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode
TL;DR: In E. coli, the presence of certain group VIIIb transition metal compounds in concentrations of about 1–10 parts per million of the metal in the culture medium causes an inhibition of the cell division process, which implies that the growth process is not markedly affected.
Journal ArticleDOI
Arene ruthenium(II) complexes formed by dehydrogenation of cyclohexadienes with ruthenium(III) trichloride
TL;DR: In this article, the same authors compared their results with available data on arene exchange in arenetricarbonylchromium complexes and discussed in terms of electronic and steric effects on metal-arene bonding.
Journal ArticleDOI
From bench to bedside – preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A)
Christian G. Hartinger,Stefanie Zorbas-Seifried,Michael A. Jakupec,Bernd Kynast,Haralabos Zorbas,Bernhard K. Keppler +5 more
TL;DR: The preclinical and early clinical development of KP1019 - from bench to bedside - is recapitulated and promising activity against certain types of tumors is observed.
Journal ArticleDOI
A Phase I and Pharmacological Study with Imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a Novel Ruthenium Anticancer Agent
Jeany M. Rademaker-Lakhai,Desiree H.J.G. van den Bongard,Dick Pluim,Jos H. Beijnen,Jan H.M. Schellens +4 more
TL;DR: The maximum-tolerated dose (MTD), profile of adverse events, and dose-limiting toxicity of NAMI-A in patients with solid tumors were determined and the ruthenium pharmacokinetic analysis revealed a linear relationship between dose and area under the concentration-time curve (AUC) of total and unbound rUThenium.
Journal ArticleDOI
Metals in Medicine
Zijian Guo,Peter J. Sadler +1 more
TL;DR: In the fight against cancer cisplatin, one of the world's best selling anticancer drugs, is being joined by other platinum, titanium, and ruthenium complexes, and metal-targeted organic agents show exciting clinical potential.